Novartis Ag (NVS) FCF Margin Growth (3y) (2012 - 2026)
Powered by 
Analysis
Novartis Ag (NVS) FCF Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 1,461.00 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | -2,596.00 |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 874.00 |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 982.00 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 1,832.00 |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 1,733.00 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | -176.00 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 1,592.00 |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | -2,476.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 982.00 |
| Mar 31, 2026 | 173.00 |
| Dec 31, 2025 | 973.00 |
| Sep 30, 2025 | 269.00 |
| Jun 30, 2025 | 1,838.00 |
| Mar 31, 2025 | 1,425.00 |
| Dec 31, 2024 | 359.00 |
| Sep 30, 2024 | 1,103.00 |
| Jun 30, 2024 | 645.00 |
| Mar 31, 2024 | 192.00 |
| Dec 31, 2023 | 2,391.00 |
| Sep 30, 2023 | 1,984.00 |
| Jun 30, 2023 | -377.00 |
| Mar 31, 2023 | 643.00 |
| Dec 31, 2022 | -527.00 |
| Sep 30, 2022 | 669.00 |
| Jun 30, 2022 | 257.00 |
| Mar 31, 2022 | -893.00 |
| Dec 31, 2021 | -19.00 |
| Sep 30, 2021 | 115.00 |